What it's for (Indications)
- Spironolactone + hydrochlorothiazide is a fixed-dose combination medication primarily indicated for the management of essential hypertension and edema.
- This combination is particularly beneficial in patients who require dual diuretic therapy with an aldosterone antagonist to optimize fluid balance and blood pressure control.
- Specifically, it is used for edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome, where fluid retention is a significant clinical problem.
- In essential hypertension, it is often prescribed when a patient requires additional blood pressure reduction beyond a single agent, or when a thiazide diuretic alone causes hypokalemia, as spironolactone's potassium-sparing effect counteracts this adverse event.
- The synergistic action of both components allows for effective diuresis and antihypertensive activity while mitigating electrolyte disturbances.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of spironolactone + hydrochlorothiazide must be highly individualized based on the patient's clinical response, severity of the condition being treated, and careful monitoring of electrolyte balance and renal function. It is administered orally, typically once daily, although dosage may be divided into two daily doses depending on the specific combination strength and physician's discretion. Available fixed-dose combinations include strengths such as 25 mg spironolactone / 25 mg hydrochlorothiazide and 50 mg spironolactone / 50 mg hydrochlorothiazide. For hypertension, treatment usually begins with a lower strength, adjusted upwards as needed to achieve target blood pressure while minimizing side effects. For edema, an initial higher dose may be required, followed by a lower maintenance dose once fluid balance is achieved. It is generally recommended to take this medication with food to enhance the absorption of spironolactone. Regular monitoring of serum electrolytes (especially potassium, sodium, and magnesium), blood urea nitrogen (BUN), and serum creatinine is crucial throughout therapy to ensure patient safety and optimize therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- The combination of spironolactone and hydrochlorothiazide can lead to various side effects, reflecting the actions of both components.
- Common adverse reactions attributable to hydrochlorothiazide include dizziness, lightheadedness, nausea, vomiting, diarrhea, headache, and orthostatic hypotension.
- Electrolyte imbalances such as hyponatremia, hypomagnesemia, and hypercalcemia can occur, along with metabolic disturbances like hyperglycemia and hyperuricemia.
- Photosensitivity reactions and rash are also possible.
- Spironolactone-specific side effects include the significant risk of hyperkalemia, particularly in patients with renal impairment, diabetes, or those concurrently taking other potassium-sparing agents, ACE inhibitors, or NSAIDs.
- Other spironolactone-related adverse effects include gynecomastia (in males), breast tenderness, menstrual irregularities, postmenopausal bleeding, decreased libido, impotence, hirsutism, and voice deepening.
- Less common but serious side effects can include acute kidney injury, pancreatitis, blood dyscrasias (e.
- g.
- , thrombocytopenia, agranulocytosis), severe skin reactions (e.
- g.
- , Stevens-Johnson syndrome, toxic epidermal necrolysis), and acute transient myopia with secondary angle-closure glaucoma (due to hydrochlorothiazide).
- Close monitoring for all potential side effects, especially electrolyte disturbances, is essential.
Serious Warnings
- Black Box Warning: None
- Several critical warnings and precautions are associated with the use of spironolactone + hydrochlorothiazide.
- The most significant concern is the potential for **hyperkalemia**, which can be life-threatening.
- The risk is significantly increased in patients with impaired renal function, diabetes mellitus, the elderly, or those receiving concomitant potassium supplements, ACE inhibitors, angiotensin receptor blockers (ARBs), or nonsteroidal anti-inflammatory drugs (NSAIDs).
- Regular monitoring of serum potassium levels is mandatory.
- The drug is contraindicated in patients with anuria, acute renal insufficiency, or significant impairment of renal excretory function due to increased risk of hyperkalemia.
- Caution is advised in patients with hepatic impairment, as electrolyte and fluid imbalance can precipitate hepatic coma.
- Hypersensitivity reactions, including cross-sensitivity to other sulfonamide-derived drugs, are possible.
- Hydrochlorothiazide has been associated with an increased risk of non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) with long-term use; patients should be advised to limit sun exposure and undergo regular skin examinations.
- Acute transient myopia and acute angle-closure glaucoma have been reported with hydrochlorothiazide, necessitating immediate discontinuation if symptoms occur.
- This combination may also exacerbate or activate systemic lupus erythematosus.
- Patients should be monitored for symptomatic hypotension, especially if volume-depleted.
How it Works (Mechanism of Action)
Spironolactone + hydrochlorothiazide is a synergistic diuretic combination that exerts its effects through two distinct pharmacological mechanisms within the renal tubules. **Hydrochlorothiazide (HCTZ)**, a thiazide diuretic, primarily acts on the distal convoluted tubule. Here, it inhibits the active reabsorption of sodium and chloride ions by blocking the Na+-Cl− symporter (NCC) on the luminal membrane. This inhibition leads to an increased excretion of sodium, chloride, and consequently, water. HCTZ also causes increased potassium and magnesium excretion while reducing calcium excretion. Its antihypertensive effect is not only due to initial volume reduction but also involves a decrease in peripheral vascular resistance with chronic administration. **Spironolactone**, a potassium-sparing diuretic, functions as a competitive antagonist of aldosterone. It primarily acts in the collecting ducts and cortical collecting tubules. Aldosterone normally promotes the reabsorption of sodium and water and the excretion of potassium by binding to mineralocorticoid receptors. By blocking these receptors, spironolactone prevents aldosterone's action, leading to increased sodium and water excretion and decreased potassium excretion. This potassium-sparing effect is crucial as it counteracts the hypokalemia often induced by hydrochlorothiazide, thereby maintaining electrolyte balance. The combined action provides more potent diuresis and antihypertensive effects than either agent alone, while minimizing the risk of potassium imbalances.
Commercial Brands (Alternatives)
No other brands found for this formula.